Commentary: Pharmacy benefit managers, not Big Pharma, responsible for high drug prices

The Business Journals

Center

High Factuality

Media Conglomerate: Advance Publications

Commentary: Pharmacy benefit managers, not Big Pharma, responsible for high drug prices

The media has written extensively about GSK's decision to stop selling its branded asthma inhaler Flovent and to replace it with a generic version. Outlets such as Fox Business and U.S. News and World Report have reported on the topic, but, remarkably, the stories fail to enlighten readers on why GSK chose to switch to a cheaper generic version of its inhaler. Many of the stories seem to have been written by the same reporters, with industry cri…